The NQO1 C609T polymorphism and risk of lung cancer: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 3091-3095

  Liu, Yin ^a   Zhang, Deping ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Chinese; Ethnicity; Lung cancer; Meta analysis; NQO1; Polymorphism

Indexed keywords

EID: 84863333635     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alexandrie AK, Nyberg F, Warholm M, et al(2004). Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev, 13, 908-14.
2. Asher G, Lotem J, Cohen B, et al(2001). Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc Natl Acad Sci USA, 98, 1188-93.
3. Begleiter A, Fourie J (2004). Induction of NQO1 in cancer cells. Methods Enzymol, 382, 320-51.
4. Benhamou S, Voho A, Bouchardy C (2001). Role of NAD(P)H: quinone oxidoreductase polymorphism at codon 187 in susceptibility to lung, laryngeal and oral/pharyngeal cancers. Biomarkers, 6, 440-7.
5. Bock CH, Wenzlaff AS, Cote ML, et al(2005). NQO1 T allele associated with decreased risk of later age at diagnosis lung cancer among never smokers: results from a population-based study. Carcinogenesis, 26, 381-6.
6. Chao C, Zhang ZF, Berthiller J, et al (2006). NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis. Cancer Epidemiol Biomarkers Prev, 15, 979-87.
7. Chen H, Lum A, Seifried A, et al(1999). Association of the NAD(P)H:quinone oxidoreductase 609C- >T polymorphism with a decreased lung cancer risk. Cancer Res, 59, 3045-8.
8. Cote ML, Yoo W, Wenzlaff AS, et al(2009). Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis, 30, 626-35.
9. Eom SY, Zhang YW, Kim SH, et al(2009). Influence of NQO1, ALDH2, and CYP2E1 genetic polymorphisms, smoking, and alcohol drinking on the risk of lung cancer in Koreans. Cancer Causes Control, 20, 137-45.
10. Hamajima N, Matsuo K, Iwata H, et al(2002). NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol, 7, 103-8.
11. Key TJ, Saracci R, Riboli E, et al(2007). Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol, 18, 1230-42.
12. Lan Q, Mumford JL, Shen M, et al(2004). Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis, 25, 2177-81.
13. Lawson KA, Woodson K, Virtamo J, et al(2005). Association of the NAD(P)H:quinone oxidoreductase (NQO1) 609C->T polymorphism with lung cancer risk among male smokers. Cancer Epidemiol Biomarkers Prev, 14, 2275-6.
14. Lewis SJ, Cherry NM, Niven RM, et al(2001). Polymorphisms in the NAD(P)H: quinone oxidoreductase gene and small cell lung cancer risk in a UK population. Lung Cancer, 34, 177-83.
15. Liang GY, Pu YP, Yin LH (2004). Studies of the genes related to lung cancer susceptibility in Nanjing Han population, China. Yi Chuan, 26, 584-8.
16. Lin P, Hsueh YM, Ko JL, et al(2003). Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. Lung Cancer, 40, 123-9.
17. Lin P, Wang HJ, Lee H, et al(1999). NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan. J Toxicol Environ Health , 58, 187-97.
18. Lin YH, Lu XL, Shao M (2000). NAD(P)H: quinone oxidoreductase gene polymorphism and susceptibility of lung cancer. Chinese J of Cancer, 19, 450-2.
19. Nebert DW, Roe AL, Vandale SE, et al(2002). NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review. Genet Med, 4, 62-70.
20. Rosvold EA, McGlynn KA, Lustbader ED, et al(1995). Identification of an NAD (P) H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5, 199-206.
21. Saldivar SJ, Wang Y, Zhao H, et al(2005). An association between a NQO1 genetic polymorphism and risk of lung cancer. Mutat Res, 582, 71-8.
22. Skuladottir H, Autrup H, Autrup J, et al(2005). Polymorphisms in genes involved in xenobiotic metabolism and lung cancer risk under the age of 60 years. A pooled study of lung cancer patients in Denmark and Norway. Lung Cancer, 48, 187-99.
23. Smith MT (1999). Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci USA, 96, 7624-6.
24. Sørensen M, Autrup H, Tjønneland A, et al(2005). Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett, 221, 185-90.
25. Su J, Niu RG, Han XY (2009). Association between polymorphisms of phaseII metabolic gene NQO1 and susceptibility to lung cancer. Chin J Public Health, 25, 458-60.
26. Sunaga N, Kohno T, Yanagitani N, et al(2002). Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev, 11, 730-8.
27. Timofeeva M, Kropp S, Sauter W, et al(2010). Genetic polymorphisms of MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk factors of early-onset lung cancer. Int J Cancer, 127, 1547-61.
28. Vineis P, Veglia F, Garte S, et al(2010). Ubiquitin-independent p53 proteasomal degradation. Cell Death Differ, 17, 103-8.
29. Wiencke JK, Spitz MR, McMillan A, et al(1997). Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism. Cancer Epidemiol Biomarkers Prev, 6, 87-92.
30. Xu LL, Wain JC, Miller DP, et al(2001). The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev, 10, 303-9.
31. Yang M, Choi Y, Hwangbo B, et al(2007). Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer, 57, 135-42.
32. Yin L, Pu Y, Liu TY, et al(2001). Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer, 33, 133-41